Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,393 result(s) found. Displaying page 1,814 of 2,220.
    «« First « Previous 1810  1811  1812  1813  1814  1815  1816  1817  1818  Next» Last»»
    EudraCT Number: 2020-004101-32 Sponsor Protocol Number: D4325C00001 Start Date*: 2021-04-06
    Sponsor Name:AstraZeneca
    Full Title: A Phase 2b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozin in Patients w...
    Medical condition: Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Completed) BG (Completed) DK (Completed) IT (Completed) ES (Restarted) SK (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2020-004198-38 Sponsor Protocol Number: KPL-716-C201 Start Date*: Information not available in EudraCT
    Sponsor Name:Kiniksa Pharmaceuticals, Ltd.
    Full Title: KPL-716-C201: A Phase 2a/b, Randomized, Double-Blind, Placebo Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects wit...
    Medical condition: Pruritus in Subjects with Prurigo Nodularis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10037084 Prurigo nodularis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) FR (Completed) BE (Completed) IT (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004228-41 Sponsor Protocol Number: C0251002 Start Date*: 2021-07-28
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS
    Medical condition: Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) HU (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-005328-13 Sponsor Protocol Number: ALXN1210-TMA-315 Start Date*: 2021-10-04
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants Who Have Thrombotic Microangiopathy Associated wi...
    Medical condition: thrombotic microangiopathy associated with a trigger
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043645 Thrombotic microangiopathy PT
    20.0 10047065 - Vascular disorders 10062198 Microangiopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005263-31 Sponsor Protocol Number: LEVOKETO_02-2020 Start Date*: 2021-06-02
    Sponsor Name:NTC SRL
    Full Title: Assessment of the effects and tolerability of RD03/2016 (Levofloxacin; Ketorolac Trometamol 0.5+0.5% w/v eye drops solution) for the treatment of bacterial conjunctivitis in adults: a multicentre, ...
    Medical condition: Bacterial conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061784 Conjunctivitis bacterial PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Completed) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000085-14 Sponsor Protocol Number: D3258C00001 Start Date*: Information not available in EudraCT
    Sponsor Name:AstraZeneca AB
    Full Title: A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled 3-Part Phase 3 Study to Demonstrate the Efficacy and Safety of Benralizumab in Patients with Eosinophilic Gastritis and/...
    Medical condition: Eosinophilic Gastritis and/or Gastroenteritis
    Disease: Version SOC Term Classification Code Term Level
    23.0 10017947 - Gastrointestinal disorders 10083619 Eosinophilic gastritis PT
    20.1 10017947 - Gastrointestinal disorders 10017902 Gastroenteritis eosinophilic PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) NL (Completed) PL (Completed) IT (Completed) FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004348-27 Sponsor Protocol Number: CB8025-32048 Start Date*: 2021-07-07
    Sponsor Name:CymaBay Therapeutics, Inc.
    Full Title: RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an In...
    Medical condition: Primary biliary cholangitis (PBC, formerly known as primary biliary cirrhosis) is a serious and potentially life threatening autoimmune disease of the liver characterized by impaired bile flow (c...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) FR (Completed) PL (Completed) NL (Completed) IT (Completed) AT (Completed) DK (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-004703-14 Sponsor Protocol Number: ACT16404 Start Date*: 2021-05-12
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A randomized, double-blind, placebo controlled, proof of concept study assessing the efficacy and safety of the RIPK1-inhibitor SAR443122 in patients with moderate to severe subacute or discoid/chr...
    Medical condition: Cutaneous Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10056509 Cutaneous lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004246-11 Sponsor Protocol Number: EDO-S101-1002 Start Date*: 2021-09-30
    Sponsor Name:Mundipharma Research Limited
    Full Title: A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients with Ad...
    Medical condition: • Cohort 1: Relapsed/refractory Small Cell Lung Cancer • Cohort 2: Relapsed/refractory Soft Tissue Sarcoma • Cohort 3: Relapsed/refractory Triple-Negative Breast Cancer • Cohort 4: Relapsed/refr...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10041071 Small cell lung cancer stage unspecified LLT
    23.0 100000004864 10084066 Triple negative breast cancer metastatic LLT
    20.0 100000004864 10033130 Ovarian cancer NOS LLT
    21.0 100000004864 10014735 Endometrial cancer NOS LLT
    20.0 100000004864 10002479 Angiosarcoma NOS LLT
    21.1 100000004864 10057043 Dermatofibrosarcoma LLT
    21.1 100000004864 10015103 Epithelioid sarcoma NOS LLT
    20.0 100000004864 10024193 Leiomyosarcoma NOS LLT
    20.0 100000004864 10024631 Liposarcoma NOS LLT
    22.1 100000004864 10082807 Solitary fibrous tumor LLT
    20.0 100000004864 10042866 Synovial sarcoma NOS LLT
    21.1 100000004864 10025556 Malignant fibrous histiocytoma NOS LLT
    20.0 100000004864 10029276 Neurofibrosarcoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001788-26 Sponsor Protocol Number: APHP201183 Start Date*: 2021-07-02
    Sponsor Name:Assistance Publique - Hôpitaux de Paris
    Full Title: Interest of adding donepezil to the non-medicinal care pathway recommended in France for Alzheimer's disease: CHOLINE-2 study
    Medical condition: Newly diagnosed patient with mild to moderate Alzheimer's disease meeting IWG-2 research diagnostic criteria including positivity for Alzheimer's disease biomarkers.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005098-29 Sponsor Protocol Number: 2017PZY5K7 Start Date*: 2021-07-09
    Sponsor Name:DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II
    Full Title: Novel therapeutic strategies to reduce coronary microvascular obstruction and to OPTImize non-culprit stenoses revascularization in ST-Elevation acute Myocardial Infarction Randomized, no-profit, ...
    Medical condition: Patients with acute ST-elevation myocardial infarction (STEMI) and multivessel coronary artery disease (MVD) defined by at least one non-culprit stenosis (NCS) with angiographic severity between 3...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10007582 Cardiac insufficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005011-52 Sponsor Protocol Number: BIA-91067-303 Start Date*: 2021-05-12
    Sponsor Name:BIAL – Portela & Cª, S.A.
    Full Title: A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel Group Study to Evaluate the Efficacy and Safety of Opicapone, as Add on to Stable Levodopa (L-DOPA) Plus a Dopa Decarboxylase ...
    Medical condition: Early Idiopathic Parkinson’s disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) PT (Completed) FR (Completed) BE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005287-60 Sponsor Protocol Number: GBT2104-132 Start Date*: 2021-11-10
    Sponsor Name:Global Blood Therapeutics, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso occlusive Crises
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005532-29 Sponsor Protocol Number: A0001B Start Date*: 2021-04-27
    Sponsor Name:Toscana Life Sciences Sviluppo
    Full Title: Randomized, placebo-controlled, double-blind, multicenter, seamless adaptive phase II-III clinical trial to select the dose and evaluate safety and efficacy of MAD0004J08 monoclonal antibody in adu...
    Medical condition: SARS-CoV2 treatment.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002385-32 Sponsor Protocol Number: APHP211057 Start Date*: 2022-08-31
    Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP)
    Full Title: Immediate versus delayed treatment with azathioprine or rituximab in anti-myelin oligodendrocytes glycoprotein (anti-MOG) antibodies associated acute demyelinating syndromes in children: a randomiz...
    Medical condition: myelin oligodendrocytes glycoprotein antibody associated diseases (MOGAD)
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002320-25 Sponsor Protocol Number: UC_0106/1712 Start Date*: 2018-07-03
    Sponsor Name:UNICANCER
    Full Title: Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: A phase II randomized study by the UNICANCER with cooperation of AFSOS.
    Medical condition: Colorectal cancer stage II/III with adjuvant oxaliplatin-based chemotherapy (simplified FOLFOX4)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005457-25 Sponsor Protocol Number: PCN-101-21 Start Date*: 2021-08-30
    Sponsor Name:Perception Neuroscience, Inc
    Full Title: A randomized, placebo-controlled, double-blind study to assess the safety and efficacy of intravenous PCN-101 in treatment-resistant depression
    Medical condition: Treatment-resistant depression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10012378 Depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005483-66 Sponsor Protocol Number: RASTA Start Date*: 2021-11-18
    Sponsor Name:UNIVERSITÀ DEGLI STUDI MILANO BICOCCA
    Full Title: ERAS versus ERAS plus arTificiAl nutrition in open pancreatoduodenectomy (The RASTA trial)
    Medical condition: Periampullary or pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10033644 Pancreaticoduodenectomy PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061902 Pancreatic neoplasm PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005078-25 Sponsor Protocol Number: CHUBX2019/59 Start Date*: 2023-01-25
    Sponsor Name:CHU de Bordeaux
    Full Title: Phase III randomized, multicenter open label study to evaluate the efficacy of immunomodulatory therapy in case of psychiatric disorders with proven dysimmunity.
    Medical condition: Mental and behavioral disorders (F00-F99)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000694-85 Sponsor Protocol Number: VX20-121-103 Start Date*: 2021-12-03
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous ...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NO (Completed) SE (Completed) DE (Completed) DK (Completed) IE (Completed) IT (Completed) GR (Completed) BE (Completed) AT (Completed) NL (Completed) PL (Completed) HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1810  1811  1812  1813  1814  1815  1816  1817  1818  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 03 16:43:30 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA